key: cord-0923232-e82ewbw2
authors: Dimopoulos, George; Almyroudi, Maria-Panagiota; Myrianthefs, Pavlos; Rello, Jordi
title: COVID-19-associated pulmonary aspergillosis (CAPA)
date: 2021-08-07
journal: Journal of Intensive Medicine
DOI: 10.1016/j.jointm.2021.07.001
sha: 6fcf3653d24399d118ea4bc033f92a61a6abb61b
doc_id: 923232
cord_uid: e82ewbw2

Invasive pulmonary aspergillosis (IPA) has been recognized as a possible secondary infection complicating Coronavirus disease 2019 (COVID-19) and increasing mortality. The aim of this review was to report and summarize the available data in the literature concerning the incidence, pathophysiology, diagnosis, and treatment of COVID-19-associated pulmonary aspergillosis (CAPA). Currently, the incidence of CAPA is unclear due to different definitions and diagnostic criteria used among the studies. It was estimated that approximately 8.6% (206/2383) of mechanically ventilated patients were diagnosed with either proven, probable, or putative CAPA. Classical host factors of invasive aspergillosis are rarely recognized in patients with CAPA, who are mainly immunocompetent presenting with comorbidities, while the role of steroids warrants further investigation. Direct epithelial injury and diffuse pulmonary microthrombi in combination with immune dysregulation, hyperinflammatory response, and immunosuppressive treatment may be implicated. Discrimination between two forms of CAPA (i.e., tracheobronchial and parenchymal) is required, whereas radiological signs of aspergillosis are not typically evident in patients with severe COVID-19 pneumonia. In previous studies, the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria, a clinical algorithm to diagnose Invasive Pulmonary Aspergillosis in intensive care unit patients (AspICU algorithm), and influenza-associated pulmonary aspergillosis (IAPA) criteria were used for the diagnosis of proven/probable and putative CAPA, as well as the differentiation from colonization, which can be challenging. Aspergillus fumigatus is the most commonly isolated pathogen in respiratory cultures. Bronchoalveolar lavage (BAL) and serum galactomannan (GM), beta-d-glucan (with limited specificity), polymerase chain reaction (PCR), and Aspergillus-specific lateral-flow device test can be included in the diagnostic work-up; however, these approaches are characterized by low sensitivity. Early treatment of CAPA is necessary, and 71.4% (135/189) of patients received antifungal therapy, mainly with voriconazole (VRC), isavuconazole (ISV), and liposomal amphotericin B (L-AMB). Given the high mortality rate among patients with Aspergillus infection, the administration of prophylactic treatment is debated. In conclusion, different diagnostic strategies are necessary to differentiate colonization from bronchial or parenchymal infection in intubated COVID-19 patients with Aspergillus spp. in their respiratory specimens vs. those not infected with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Following confirmation, VRC or ISV should be used for the treatment of CAPA.

Typically, patients with Coronavirus disease 2019 (COVID-19) are immunocompetent, of advanced age, and with comorbidities (mainly hypertension, diabetes, chronic heart, and renal disease). [1] [2] [3] Approximately 5% of those will develop a severe form of the disease with respiratory failure, complex immune dysregulation, and cytokine storm, requiring hospitalization in the intensive care unit (ICU). [4] Different studies showed that these patients are at increased risk of secondary infections. [5] The syndromes of pulmonary aspergillosis complicating severe viral infections are distinct from classic invasive pulmonary aspergillosis (IPA). IPA, particularly that associated with hematologic malignancies and transplantation, is most frequently encountered in patients with neutropenia and other immunocompromised individuals. Numerous studies have recognized influenza-associated pulmonary aspergillosis (IAPA) as respiratory epithelium damage. Of note, local anosoparalysis may render patients with influenza more susceptible to IPA. [6, 7] Since the first evidence of secondary aspergillosis reported in China, several studies have shown that steroid and other immune-modulatory therapies are linked to an increased risk of a similar syndrome associated with severe COVID-19, termed COVID-19-associated pulmonary aspergillosis (CAPA).

Actually, the first reports referred to post-mortem results raising concerns regarding this infection as an additional factor contributing to patient mortality. [7] [8] [9] [10] [11] [12] Three different grades (i.e., possible, probable, and proven CAPA) have been suggested by an international panel of experts, [13] enabling investigators to stratify patients in research registries and clinical trials. 3 This review focused on key controversies in CAPA due to its contribution to mortality among patients with COVID-19. An analysis of the available literature (reported until January 2021; search list presented in Appendix) was performed to identify differences in the incidence, pathophysiology, diagnosis, and treatment of CAPA and IPA.

Owing to differences in diagnostic criteria, methods, definitions, and local practices, the incidence of CAPA varies. Therefore, the estimation of CAPA incidence is challenging due to the lack of a gold standard and limitations in diagnostic tests. For this reason, definitions used for IAPA were applied in most studies; however, this approach generated a wide degree of variability in the incidence of CAPA among ICU patients (range: 3.8-34%). [7] [8] [9] [10] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In general, the diagnosis of CAPA is delayed vs. that of IAPA, and the incidence of the angioinvasive parenchymal form is lower. Table 1 shows all published studies describing the incidence of CAPA and associated comorbidities until January 2021. The majority of those studies suggested that CAPA mostly occurs in severely ill, mechanically ventilated patients with COVID-19. Among them, three prospective studies reported an incidence ranging 14-20%, while more recently published studies indicated a lower incidence ranging 3-15% (a total of 2407 patients were included). [8, 11, 26, 28, [33] [34] [35] [36] [37] [38] [39] [40] [41] Excluding seven case reports, the diagnosis of CAPA has been confirmed in 223 of 2400 ICU patients (incidence of 9.2%). Nevertheless, this percentage may be slightly lower since two studies did not report the total number of patients admitted in the ICU during the investigation period. Thus, by deducting 17 patients from those two studies, the total number of ICU patients with COVID-19 and a diagnosis of proven/probable/putative CAPA is 206 (incidence: 8.6%).

Interestingly, among eight studies involving >100 patients each, the incidence of CAPA ranged from 3.3% to 27.7%, though six of them reported an incidence <10%. This is in accordance with evidence from Chinese studies. [42, 43] Notably, the majority of CAPA cases were documented in European countries (26/32 studies); one and two studies were performed in the USA and China, respectively.

The medical history, underlying conditions, comorbidities, and risk factors related to the development of CAPA are shown in Table 1 . Two previous studies have identified long-term treatment with corticosteroids as a risk factor for infection with Aspergillus spp. [8, 28] Moreover, the role of dexamethasone (doses) in the early stage of COVID-19 and that of tocilizumab in the development of a cytokine storm warrant further investigation. [10, 44, 45] 

Currently, the pathogenesis of CAPA is not well defined. In influenza, disruption of the lung epithelium with dysfunctional mucociliary clearance, local immunoparalysis due to influenza-induced hypoxia, treatment with corticosteroids, acute respiratory distress syndrome, and suppression of the nicotinamide adenine dinucleotide phosphate oxidase complex favor tissue invasion by Aspergillus spp. In addition, invasive Aspergillus 4 tracheobronchitis has been described in approximately 55% of patients with IAPA. Examination through bronchoscopy has revealed the presence of epithelial plaques, pseudomembranes, and ulceration, as well as sporulating heads of Aspergillus spp inside the bronchi. [46] Similar to influenza, in severe COVID-19 pneumonia, destruction of the bronchial mucosa and alveolar injury caused by the virus create favorable conditions for fungal growth. [47] The main histopathological findings in 14 patients with COVID-19 were diffuse alveolar damage in the acute or organizing phase of the disease, with the virus located in the pneumocytes and tracheal epithelium, and scarce focal pulmonary microthrombi. This observation indicated that the increased pulmonary epithelial and vascular permeability facilitates the invasion of Aspergillus spp. [2, 48] It is well established that Aspergillus spp. live in the environment, and the inhalation of its spores (conidia) leads to pulmonary disease depending on the host immune status. Severe COVID-19 is frequently associated with immune dysregulation, characterized by a decrease in the number and functionality of CD4 + T and CD8 + T-cells and a hyperinflammatory state. Overexpression of pro-and anti-inflammatory cytokines contributes to a highly permissive inflammatory environment that enhances fungal growth. [49, 50] Furthermore, damage-associated molecular patterns, which are implicated in the pathogenesis of aspergillosis, are released during infection with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), thereby leading to an excessive inflammatory response and lung injury. [49] COVID-19-associated immune dysregulation and immunosuppressive treatment, rather than the pathophysiology of IPA, are host factors for CAPA. Except for corticosteroids (a known risk factor for IPA), tocilizumab (monoclonal antibody against the interleukin-6 [IL-6] receptor), interferon 1β (IFN1β), and a combination of tocilizumab with corticosteroids were more frequently administered in patients with CAPA than in those without aspergillosis (71.4% vs. 33.3%, P = 0.050; 71.4% vs. 20.9%, P ≤ 0.050; and 57.1% vs. 28.7%, P = 0.180, respectively). [51] Blockage of IL-6 inhibits the development of protective T-helper cells (Th17 cells), leading to a defective immune response against infection with Aspergillus fumigatus(A. fumigatus). In addition, it has been reported that IL-6 enhances epithelial integrity during injury while the wide use of dexamethasone in critically ill patients with COVID-19 renders these patients more susceptible to IPA. [52] The maturation of phagosomes that degrade A. fumigatus spores via the process of phagolysosomal fusion is impaired by corticosteroids compromising the host defense against the Aspergillus spp. [53] Imaging The use of computed tomography (CT) imaging may be unsuitable in these patients. It may be difficult to document changes indicative of CAPA in the parenchyma through CT imaging. This is because mechanically ventilated COVID-19 patients without invasive aspergillosis often have nodular infiltrates, complicating the identification of surrounding halos in the scans. Radiological characteristics of IPA (e.g., solitary or multiple pulmonary nodules, halo sign, reverse halo sign, ground-glass opacity, air crescent, and cavitation) may not be distinct in severe COVID-19 pneumonia, which presents in CT scans with bilateral, peripheral ground-glass opacities, crazy-paving pattern, consolidation, and bronchovascular thickening. Patti et al [54] reported a mechanically ventilated patient with COVID-19, whose CT analysis showed bilateral peripheral ground glass infiltrates, with newly formed thin-walled cavitary lesions occupied by fungal ball-like lesions. Aspergillus flavus was isolated in respiratory cultures. Moreover, a CT is not always feasible due to the risk associated with the transportation of critically ill patients. White et al [32] proposed a diagnostic algorithm for CAPA that, along with clinical and mycological criteria, incorporated typical radiological signs of IPA, the presence of new infiltrates, and evidence of sinusitis. [36] 

Regarding the mycological criteria for the diagnosis of CAPA, 85 of 208 (42%) patients included in all studies underwent bronchoscopy [ Table 2 ] (one study did not report the number of patients who underwent bronchoscopy). [26] At the start of the epidemic, the use of bronchoscopy was avoided due to shortages in personal protective equipment. In two studies, non-directed bronchoalveolar lavage (NBL) was performed; although this method is less invasive and safer than bronchoscopy, it is linked to a higher risk of sample contamination by upper respiratory flora. [28, 55] Other mycological methods, including polymerase chain reaction (PCR) and the lateral flow test, require validation. The Aspergillus-specific lateral-flow device test detects an extracellular glycoprotein antigen secreted by Aspergillus spp. only during active growth. This method has been validated in serum and BAL; it has shown a 79% sensitivity and 85% specificity for probable or proven IPA in non-COVID-19 ICU patients. [56] The lateral-flow device test was used in two cases in the literature and is currently being evaluated in patients with influenza and COVID-19 IPA [19, 22] (AspiFlu study ISRCTN51287266; https://doi.org/10.1186/ISRCTN51287266); however, it requires validation. Serial assessment of serum galactomannan (GM) (despite its low sensitivity) and serum beta-D-glucan in combination with multiple cultures of TA/bronchial aspirate or NBL and PCR testing of serum and respiratory specimens have been included in the diagnostic work-up. [50] Multiple and repetitive positive mycology tests in combination with typical radiological and clinical criteria contribute to the diagnosis of CAPA. In tracheobronchial cases suspected of CAPA, bronchial biopsies are required. Biomarkers are often negative. The use of different diagnostic criteria may contribute to the varying mortality rates reported in the literature. Indeed, the mortality rate is higher among patients with positive cultures than those with probable CAPA detected using GM. 6 Moreover, the mortality rate is higher in patients with multiple positive Aspergillus spp. results than in those with a single positive biomarker.

Systemic markers are suboptimal for the diagnosis of CAPA, with sensitivity <50%. Furthermore, some techniques require validation. The GM assay has been validated in BAL and serum, although numerous studies have also used endotracheal aspirates. The specificity of GM in BAL is suboptimal and does not satisfactorily discriminate infection from contamination. In six patients with COVID-19 acute respiratory distress syndrome and a positive value for GM in BAL, the diagnosis of probable CAPA was not confirmed post mortem. [29, 46] Thus, the identification of some "probable" cases through this approach remains uncertain.

Serum GM is a sensitive biomarker for IPA in patients with neutropenia; however, in non-neutropenic critically ill patients, serum and BAL GM exhibited a sensitivity of 25% and 88-90%, respectively. [47, 57] Similarly, in a prospective multicenter study, 28% of ICU patients who were screened for CAPA and 100% of those classified as probable CAPA had a positive BAL GM-index >1; only 1% and 3% of those had positive serum GM. [8] Overall, the GM index in serum (>0.5) and respiratory samples (BAL, NBL, TA) was positive in 37/144 (26%) and 100/129 (78%) patients [ Table 2 ]. Antifungals and chloroquine/hydroxychloroquine, which exhibit in-vitro activity against A. fumigatus, may interfere with the GM measurement and decrease its sensitivity. [52] Furthermore, the reduced release of serum GM may reflect that CAPA is characterized by more pronounced pulmonary invasion and less fungal angioinvasion. Therefore, a negative serum result cannot exclude the diagnosis of CAPA.

Although beta-D-glucan is more sensitive than serum GM, it lacks specificity because it is detected in various invasive fungal infections. [58] Its levels were elevated in 38/62 (61.3%) patients with CAPA [ Table 2 ]. Although PCR is mainly performed for patients with hematologic malignancies and hematopoietic stem cell transplants, it has shown higher sensitivity for the diagnosis of CAPA compared with cultures using respiratory samples. [30, 33] PCR using serum and/or respiratory samples was positive in 57/81 (70.4%) patients with CAPA [ Table 2 ].

Based on these findings, the revised European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) mycological criteria include PCR using BAL and serum samples; this method is recommended for screening and confirmation of the diagnosis of probable IPA. [59] 

The presentation of CAPA is variable and involves two distinct forms, namely tracheobronchial and parenchymal CAPA. It is important to distinguish between these two forms, as this may impact the diagnostic and therapeutic approaches. Discrepancies in the onset of CAPA could be due to differences between these forms, and examination through bronchoscopy may be required. The currently available literature suggests that 7 some patients with CAPA survive without receiving antifungal therapy. This indicates a potential distinction between angioinvasion and minimal invasive disease/tissue invasion.

The diagnosis of CAPA is challenging. The discrimination between invasive infection and colonization is difficult. This is because the available diagnostic tests, except for histopathological examination, do not yield absolute evidence of infection. There is considerable clinical uncertainty regarding the accurate identification of "probable" cases of CAPA. [7, 46, 59, 60] Thus far, 213 (including 7 case reports) cases of CAPA have been reported in the literature [ Table 3 ]: 6 proven and 31 probable according to the EORTC/MSG criteria [59] ; 133 putative according to the AspICU algorithm [7, 60] ; 38 probable according to the IAPA criteria proposed by Verweij et al [46] ; and 5 according to the criteria proposed by White et al [32] Four studies reported 24 cases of Aspergillus spp colonization that did not meet the clinical, mycological, and radiological criteria for classification as proven/probable or putative infection.

The EORTC/MSG criteria [ Table 4 ] are targeted toward immunocompromised patients. Host factors that are a prerequisite for the diagnosis of probable IPA are not typically present in ICU patients. [59] Additionally, histopathological confirmation in critically ill patients is difficult either due to coagulation abnormalities or the risk of complications caused by mechanical ventilation (e.g., pneumothorax). Blot et al [60] developed an AspICU algorithm concerning ICU patients. In contrast with the definition established by the EORTC/MSG, where the presence of host factors and specific radiological signs (e.g., halo sign, air-crescent sign, or a cavity) is required, the AspICU algorithm includes general radiological abnormalities observed on CT or chest X-ray examination; host factors must be present in case of negative mycological criteria in BAL.

Schauwvlieghe et al [7] proposed a modified AspICU algorithm for patients with influenza and IPA, in which the GM indices for BAL and serum are included in the mycological criteria along with a positive BAL culture and histopathologic or direct microscopic evidence of Aspergillus spp.[ Table 4 ]. A positive BAL culture was found in 60% of patients with IAPA; in the remaining patients, the diagnosis was based on a positive GM index for BAL. [32] In a prospective cohort study including 135 ICU patients with COVID-19, eight patients were classified as putative IPA based on the AspICU algorithm. Twelve more patients were identified following the application of the modified version of this algorithm. [8] Limitations of the aforementioned studies include the Table 5 ], whereas data regarding treatment were not reported for 24 patients. The main reason for not administering antifungal treatment was early death. The most commonly antifungal agent was VRC, followed by ISV and L-AMB.

Dupont et al [61] reported a non-statistically significant lower mortality rate among patients with putative aspergillosis who were treated with VRC (three deaths in nine patients [33.3%]) vs. those not treated (five deaths in 10 patients [50%])]. VRC is hepatically metabolized, and patients should be monitored for possible drug interactions with cytochrome P450 family 2 subfamily C member 19 (CYP2C19) and CYP3A.

Therapeutic drug monitoring is required as toxic levels may lead to hepatotoxicity and neurotoxicity. ISV exhibits a safer profile with less severe adverse events and fewer drug-drug interactions, while the role of L-AMB is limited by acute kidney injury complicating severe COVID-19. [51] ISV should be preferred in patients for whom liver toxicity is a concern.

Patients should also be monitored for the development of resistance by Aspergillus spp. to azoles.

Triazole-resistant A. fumigatus was isolated in a patient who was possibly exposed to organic matter. The patient expired due to massive pulmonary embolism shortly after the diagnosis of putative aspergillosis. [24] The second case reported in the literature was also a patient with daily exposure to fungicides. [23] The TR34L98H mutation in the CYP51A gene, which is associated with resistance, was identified in Aspergillus strains isolated from both patients. Susceptibility testing is recommended in regions with a resistance rate >5%. In case of azole 9 failure or in regions with a resistance rate >10%, VRC/ISV in combination with an echinocandin or L-AMB or monotherapy with L-AMB should be administered. New antifungal agents are currently evaluated in clinical trials. Rezafungin, which belongs to echinocandins, and ibrexafungerp (formerly termed SCY-078), which inhibits 1,3-beta-D-glucan synthase, have shown in-vitro activity against Aspergillus spp., including azoleresistant A. fumigatus isolates. The antifungal agents olorofim and fosmanogepix, which have also demonstrated activity against Aspergillus spp., are currently under development. [62] The diagnosis of CAPA is challenging, and patients with severe COVID-19 pneumonia complicated by IPA may be associated with a worse prognosis. Therefore, the administration of prophylactic treatment with posaconazole, VRC, itraconazole, or inhaled amphotericin B (recommended for prophylaxis in patients with hematological malignancies and transplants) is currently under debate. Rutsaert et al [10] after finding an unexpected number of COVID-19 patients with suspected IPA, subsequently used nebulized L-AMB (12.5 mg) for prophylaxis in every mechanically ventilated patient they treated. Nevertheless, this approach was linked to a risk of sudden complications in ventilated patients due to obstruction of expiratory filters. In this study, the rate of all-cause mortality was 55%, while a significantly higher 30-day mortality rate was observed in patients with CAPA vs. those without CAPA (44% vs. 19%, P = 0.002 and 74% vs. 26%, P < 0.001 for probable and putative IPA, respectively). [8] Indeed, there is a general consensus against the use of prophylactic therapy in patients with COVID-19. This position was supported by a recent randomized clinical trial, which failed to show significant benefit after the administration of prophylactic therapy. [63] 

The incidence of CAPA appears lower than that of IAPA, but varies regionally. In addition, it is influenced by differences in the standard of care, risk conditions, and poor performance of diagnostic tests. Different diagnostic strategies are necessary to differentiate colonization from bronchial or parenchymal infection in intubated COVID-19 patients with Aspergillus spp. in their respiratory specimens vs. those not infected with SARS-CoV-2. The usefulness of imaging techniques (e.g., CT scans) in the diagnosis of CAPA in patients with COVID-19 is limited, whereas bronchoscopy (under safe conditions) is adding value to the diagnostic process.

Following confirmation, VRC or ISV should be used for the treatment of CAPA. The appropriate treatment duration for CAPA is currently unknown.

JR served in the speakers bureau and as a consultant for Pfizer. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. [27] Switzerland ICU, 118 (3.8) AH, DM, Obesity, Pulmonary fibrosis, BA Van Biesen et al [28] Netherlands ICU, 42 (21.4) COPD, DM, AH, Chronic steroid treatment, Neutropenia, Stem cell transplant,

Flikweert et al [29] Netherlands ICU, Nasir et al [26] 0/5 1/5 NA NA NA 5/5 A. flavus (4),

A. niger (1) Alanio et al [9] 1/9 4/9 9/9 2/9 4/9 7/9 A. fumigatus Dupont et al [61] 1/12 NA 9/19 5/8 NA 16/19 A. fumigatus (14) A. calidoustus (1) A. niger (1) Prattes et al [19] 0/1 0/ A. flavus (2) al [51] A. niger (2) Patti et al [54] Helleberg et al [31] 1/2 NA 1/2 2/2 NA 2/2 A. fumigatus (2) Trujillo et al [65] 0/1 1/1 0/1

Spadea et al [66] 1/1 1/1 0/1 0/1 NA NA Van Biesen et al [28] NA NA 0/9 9/9 NA 7/9 A. fumigatus (5),

A. terreus (1) Lamoth et al [27] 1 al [24] Falces-Romero et al [30] 1 

A. flavus (1) van Arkel et al [17] 0/3 NA 3/6 3/3 NA 5/6 A. fumigatus (5) Rutsaert et al [10] 1/6 NA 6/7 6/6 NA 6/7 A. flavus (1), A. fumigatus (5) [36] Prospective EORTC/MSG modified AspICU 0

Koehler et al [16] Retrospective Modified AspICU algorithm 0

Nasir et al [26] Retrospective Modified AspICU algorithm 0

Alanio et al [9] Prospective EORTC/MSG modified AspICU 0

Dupont et al [61] Prospective Modified AspICU algorithm 0

Prattes et al [19] Case report AspICU algorithm 0

Wang et al [21] Retrospective EORTC/MSG 0 8 0 0 0 NA Bruno et al [64] Case report Modified AspICU algorithm 0

Meijer et al [22] Case report Modified AspICU algorithm 0

al [25] Case report Post-mortem al [51] Prospective EORTC/MSG 0 7 0 0 0 5/7

Patti et al [54] Case report IAPA criteria 0 0 0 1 0 0/1 White et al [32] Prospective AspICU algorithm, Helleberg et al [31] Case series AspICU algorithm 0

Trujillo et al [65] Case report EORTC/MSG 0

al [66] Case report EORTC/MSG 0

Van Biesen et al [28] Cohort study AspICU algorithm 0 0 9 0 0 2/9

Lamoth et al [27] Cohort study Modified AspICU algorithm,

Mitaka et al [67] Retrospective AspICU algorithm 0

Nasri et al [68] Case report EORTC/MSG 0

Gangneux et al [33] Prospective AspICU Montes et al [58] AspICU algorithm Blaize et al [18] Case report AspICU algorithm 0

Schein et al [55] Case report EORTC/MSG 0

Fernandez et al [69] Case report EORTC/MSG 0

Ghelfenstein-Ferreira et al [24] Case report AspICU algorithm 0

Falces-Romero et al [30] Retrospective EORTC/MSG, AspICU algorithm 0

Mohamed et al [23] Case report AspICU algorithm 0

Antinori et al [20] Case report EORTC/MSG post mortem

Lahmer et al [34] Case report AspICU algorithm 0

Chauvet et al [41] Retrospective EORTC/MSG, Bartoletti et al [8] Prospective IAPA criteria 0 0 0 30 0 13/30

van Arkel et al [17] Cohort study IAPA criteria 0 0 0 6 0 4/6

Rutsaert et al [10] Case series AspICU 

-Dense, well-circumscribed lesions(s) with or without a halo sign.

-Air crescent sign.

-Cavity.

-Wedge-shaped and segmental or lobar consolidation.

-Aspergillus recovered by culture from sputum, BAL, bronchial brush, or aspirate.

-Microscopical detection of fungal elements in sputum, BAL, bronchial brush, or aspirate indicating a mold.

-GM antigen detected in plasma, serum, BAL. Any 1 of the following: 

A host factor and a clinical feature but not mycological evidence AspICU algorithm, 2012 [60] Putative (all four criteria must be met): 133/213 (62.4%/) CAPA cases

 Fever refractory to at least 3 days of appropriate antibiotic therapy.

 Recrudescent fever after a period of defervescence of at least 48 h while still on antibiotics and without other apparent cause.

 Pleuritic chest pain or pleuritic rub.

 Dyspnea.

 Hemoptysis.

 Worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory support.

4a.

Host risk factors (one of the following conditions)

 Neutropenia (absolute neutrophil count < 500/mm 3 ) preceding or at the time of ICU admission  Underlying hematological or oncological malignancy treated with cytotoxic agents  Glucocorticoid treatment (prednisone equivalent, >20 mg/day)  Congenital or acquired immunodeficiency 4b. Semiquantitative Aspergillus-positive culture of BAL fluid (+ or ++), without bacterial growth together with a positive cytological smear showing branching hyphae

When ≥1 criterion necessary for a diagnosis of putative IPA is not met

Modified AspICU algorithm, 2018 [7] AspICU algorithm 1,2,3

One or more of the following:

 Histopathology or direct microscopic evidence of dichotomous septate hyphae with positive culture for Aspergillus from tissue  A positive Aspergillus culture from a BAL.

A GM optical index on serum of ≥0.5.

IAPA criteria 2020 [46] Probable: 38 

Machado et al [36] 5/8 ISV (4), L-AMB (2), VRC (2) Koehler et al [16] 5/5 VRC (4), ISV (1) Nasir et al [26] 5/5 L-AMB (2), VRC (3) Alanio et al [9] 2/9 VRC (1), Caspofungin (1) Dupont et al [61] 9/19 VRC (9) Prattes et al [19] 1/1 VRC (1) Wang et al [21] NA NA Bruno et al [64] 1/1 VRC (1) Meijer et al [22] 1/1 VRC (1) Santana et al [25] 0/1 NA Borman et al [35] NA NA Segrelles-Calvo et al [51] 4/7 L-AMB (1), Itraconazole (3) Patti et al [54] 1/1 VRC (1) White et al [32] 17/25 VRC (16), L-AMB (6), Caspofungin + VRC (2), L-AMB + Anidulafungin (1) Helleberg et al [31] 2/2 VRC (2) Trujillo et al [65] 1/1 ISV+ neb L-AMB (1) Spadea et al [66] 1/1 L-AMB (1) Van Biesen et al [28] 9/9 L-AMB + VRC (9) Lamoth et al [27] 3/3 VRC (3) Mitaka et al [67] 4/4 VRC (3), Caspofungin (1) Nasri et al [68] 1/1 L-AMB (1) Gangneux et al [33] 7/7 VRC or ISV Roman-Montes et al [58] 12/14 VRC (10), Anidulafungin (2) Blaize et al [18] 0/1 NA Schein et al [55] 1/1 VRC (1)

Fernandez et al [69] 1/1 VRC (1)

Ghelfenstein-Ferreira et al [24] 0/1 NA Falces-Romero et al [30] 6/8 VRC (4), VRC + Caspofungin (1), L-AMB (5), ISV (2) 

Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: A systematic review of the literature

Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity

COVID-19: Consider cytokine storm syndromes and immunosuppression

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Pulmonary aspergillosis following post-influenzal bronchopneumonia treated with antibiotics

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: A prospective study

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

COVID-19-associated invasive pulmonary aspergillosis

Aspergillosis complicating severe 11 coronavirus disease

DoD COVID-19 practice Management guide: Clinical management of COVID-19

Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019

Clinical and virological data of the first cases of COVID-19 in Europe: A case series

COVID-19 associated pulmonary aspergillosis

COVID-19-associated pulmonary aspergillosis

Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient

Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -A case report

Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge

Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: A retrospective case series

Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: A Case Report

Multi-triazoleresistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination

Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU -A case report

Confirmed invasive pulmonary aspergillosis and COVID-19: The value of postmortem findings to support antemortem management

COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan

Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients

Detection of invasive pulmonary aspergillosis in COVID-19 with non-directed bronchoalveolar lavage

Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series

Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital

Epub ahead of print

Invasive aspergillosis in patients with severe COVID-19 pneumonia

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Is the COVID-19 pandemic a good time to include aspergillus molecular detection to categorize aspergillosis in ICU patients? A Monocentric Experience

Invasive pulmonary aspergillosis in severe 13 coronavirus disease 2019 pneumonia

COVID-19-associated invasive aspergillosis: Data from the UK National Mycology Reference Laboratory

Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: A French multicentric retrospective cohort

Surveillance for COVID-19-associated pulmonary aspergillosis

Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU

Risks of ventilatorassociated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease

Risk factors for invasive pulmonary aspergillosis in critically ill patients with coronavirus disease 2019-induced acute respiratory distress syndrome

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Invasive fungal diseases during COVID-19: We should be prepared

Invasive aspergillosis as an under-recognized superinfection in COVID-19

Review of influenzaassociated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion

Diagnosing COVID-19-associated pulmonary aspergillosis

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: A case series

Invasive fungal disease complicating COVID-19: When it rains it pours

COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment

Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia

Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab

Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling

Subacute aspergillosis "fungal balls" complicating COVID-19

Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report

Lateral flow assays for the diagnosis of invasive aspergillosis: Current status

bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients

Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis

Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients

Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19)

Aspergillus fumigatus and pan-azole resistance: Who should be concerned

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): A randomised, open-label, proof-of-concept trial

COVID-19-associated pulmonary aspergillosis: Adding insult to injury

Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient

Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting

Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City

Fatal invasive pulmonary 16 aspergillosis in COVID-19 patient with acute myeloid leukemia in Iran

Ventilator-associated pneumonia involving Aspergillus flavus in a patient

Cases according to AspICU algorithm is 133, EORTC/MSG criteria is 37, IAPA criteria is 38, CAPA criteria is 5

CAPA: COVID-19-associated aspergillosis

European Organization for Research and Treatment of Cancer/Mycoses Study Group; IAPA: Influenza-associated pulmonary aspergillosis

Recent history of neutropenia (<0.5 × 10 9 neutrophils/L [<500 neutrophils/mm 3 ] for >10 days) temporally related to the onset of invasive fungal disease

Hematologic malignancy

Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a therapeutic dose of ≥0.3 mg/kg corticosteroids for ≥3 weeks in the past 60 days

Treatment with other recognized T-cell immunosuppressants, such as calcineurin inhibitors, tumor necrosis factor-a blockers, lymphocyte-specific monoclonal antibodies

Treatment with recognized B-cell immunosuppressants, such as Bruton's tyrosine kinase inhibitors

Inherited severe immunodeficiency (such as chronic granulomatous disease, STAT 3 deficiency, or severe combined immunodeficiency)

Acute graft-vs.-host disease grade III or IV involving the gut, lungs, or liver that is refractory to first-line treatment with steroids

VRC + ISV (1), Caspofungin

L-AMB

COVID-19: Coronavirus disease

None.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-forprofit sectors.

Data for this work were identified by searches of MEDLINE, PubMed using the search string "(Aspergill") AND ("invasive" OR "infection" OR "case" OR "patient" OR "report") AND ("COVID*" OR "corona"), AND ("SARS-CoV-2") AND ("Aspergill*"), AND ("aspergill*") AND (guideline OR treatment OR therapy OR diagnosis). Only articles published in English until January 31, 2021 were included.